<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04854837</url>
  </required_header>
  <id_info>
    <org_study_id>REM-HD</org_study_id>
    <nct_id>NCT04854837</nct_id>
  </id_info>
  <brief_title>Safety of Remdesivir Treatment in COVID-19 Patients Requiring Hemodialysis</brief_title>
  <acronym>REM-HD</acronym>
  <official_title>Safety of Remdesivir Treatment in COVID-19 Patients Requiring Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Semmelweis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Semmelweis University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The FDA approved the antiviral drug remdesivir for use in adults for the treatment of&#xD;
      COVID-19 requiring hospitalization.&#xD;
&#xD;
      There are only limited data about the safety of the drug in hemodialysed patents. Chronic&#xD;
      kidney disease is a risk factor in COVID-19 for developing severe disease.&#xD;
&#xD;
      The aim of our investigation is to observe the safety of remdesivir among hemodialysed&#xD;
      patients requiring hospitalization for COVID-19.&#xD;
&#xD;
      We are going to compare two group's data:&#xD;
&#xD;
        1. Hemodialysed COVID-19 patients requiring hospitalization because of pneumonia and need&#xD;
           of oxygen supplementation, and admitted after 12/Apr/2021 - these patients received&#xD;
           remdesivir.&#xD;
&#xD;
        2. Hemodialysed COVID-19 patients requiring hospitalization because of pneumonia and need&#xD;
           of oxygen supplementation, and admitted before 12/Apr/2021 - these patients did not&#xD;
           receive remdesivir.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event frequency</measure>
    <time_frame>14 days after completion of treatment</time_frame>
    <description>Number of adverse events occuring through the observational period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Significant ASAT elevation</measure>
    <time_frame>continuously, 14 days after completion of treatment</time_frame>
    <description>Number of patients with significant (&gt;2× ULN or &gt;5× baseline) serum aspartate aminotransferase elevation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant ALAT elevation</measure>
    <time_frame>continuously, 14 days after completion of treatment</time_frame>
    <description>Number of patients with significant (&gt;2× ULN or &gt;5× baseline) serum alanin aminotransferase elevation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant ALP elevation</measure>
    <time_frame>continuously, 14 days after completion of treatment</time_frame>
    <description>Number of patients with significant (&gt;2× ULN or &gt;5× baseline) serum alkaline phosphatase elevation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant seBi elevation</measure>
    <time_frame>continuously, 14 days after completion of treatment</time_frame>
    <description>Number of patients with significant (&gt;2× ULN or &gt;5× baseline) serum total bilirubin elevation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of suspected drug-induced injury</measure>
    <time_frame>continuously, 14 days after completion of treatment</time_frame>
    <description>Number of patients with drug induced liver injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc prolongation</measure>
    <time_frame>continuously, 14 days after completion of treatment</time_frame>
    <description>Change in corrected QTc interval measured on 12-lead ECG, corrected by Bazett's formule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmia occurence</measure>
    <time_frame>continuously, 14 days after completion of treatment</time_frame>
    <description>Number of patients with clinically significant (judged by investigator) ECG abnormalities</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Covid19</condition>
  <condition>End Stage Renal Failure on Dialysis</condition>
  <arm_group>
    <arm_group_label>Hemodialysed patients received remdesivir</arm_group_label>
    <description>Remdesivir: day-1: 200 mg intravenously; day 2-5: 100 mg intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemodialysed patients not received remdesivir</arm_group_label>
    <description>Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remdesivir</intervention_name>
    <description>Remdesivir treatment</description>
    <arm_group_label>Hemodialysed patients received remdesivir</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hemodialysed COVID-19 patients requiring hospitalization&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients at least 18 ys. of age&#xD;
&#xD;
          -  Ability to understand and sign informed consent form&#xD;
&#xD;
          -  End stage kidney disease of any cause, requiring hemodialysis&#xD;
&#xD;
          -  COVID-19 disease (with at least one positive SARS-CoV-2 RT-PCR or COVID-19 antigene&#xD;
             quick test)&#xD;
&#xD;
          -  Radiologic evidence for pneumonia&#xD;
&#xD;
          -  Need for oxygen supplemental oxygen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemodynamically unstable patients (systolic blood pressure &lt;90Hgmm; heart&#xD;
             rate&gt;120/min)&#xD;
&#xD;
          -  Significant liver enzyme elevation at screening (ASAT or ALAT &gt;2.5×ULN)&#xD;
&#xD;
          -  QTc &gt; 470 msec at baseline ECG (Bazett formule)&#xD;
&#xD;
          -  Need for mechanical ventilation or intensive care unit admission&#xD;
&#xD;
          -  Limited life expectancy (&lt;3 months)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Balazs Szili, MD</last_name>
    <phone>+36 1 459 1500</phone>
    <phone_ext>51526</phone_ext>
    <email>szili.balazs@med.semmelweis-univ.hu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Semmelweis University - Department of Internal Medicine and Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Balazs Szili, MD.</last_name>
      <phone>+36 20 825 7052</phone>
      <email>szili.balazs@med.semmelweis-univ.hu</email>
    </contact>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Semmelweis University</investigator_affiliation>
    <investigator_full_name>Istvan Takacs</investigator_full_name>
    <investigator_title>Head of department</investigator_title>
  </responsible_party>
  <keyword>Remdesivir safety</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remdesivir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

